Electronic Drug Delivery Systems Market Scope
Electronic drug delivery systems are complex but small electronics medical devices, used to infuse drugs, growth hormones, and medicines of desired quantity in patients. It offers precise and desired functionality, wireless connectivity, and user-friendly intuitive interfaces. It allows patients to administer therapy and make patients independent of caregivers, drug regimens, and medical professionals. Technological advancements in drug delivery devices have led to the development of electronic drug delivery devices, owing to improved efficacy, cost and time effectiveness, autonomous patient-administered therapy, and minimum side effects.
Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Electronic Drug Delivery Systems market throughout the predicted period.
Merck Group (Germany), United Therapeutics Corporation (United States), Bayer AG (Germany), Insulet Corporation (United States), Tandem Diabetes Care (United States), Medtronic PLC (Ireland), F. Hoffmann-La Roche (Switzerland), Novo Nordisk (Denmark), Amgen (United States) and AstraZeneca (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Companion Medical (United States), FindAir SP. Z O. O. (Poland), ViCentra B.V. (Netherland), Canè SPA (Italy) and Debiotech S.A. (Switzerland).
About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
Segmentation Overview
The study have segmented the market of Global Electronic Drug Delivery Systems market by Type (Wearable Infusion Pumps, Autoinjectors, Injection Pens, Inhalers and Others), by Application (Cardiovascular Disease, Diabetes, Multiple Sclerosis, Respiratory Disorders and Others) and Region with country level break-up.
On the basis of geography, the market of Electronic Drug Delivery Systems has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
In November 2018, United Therapeutics has signed a licensing agreement with Arena Pharmaceuticals to commercialize Arena’s hypertensive drug - Ralinepag.
In January 2020 Medtronic plc has launched Efficio–a cloud-based management software, which can be used with SynchroMed II intrathecal drug delivery system. This software launched helped the physicians to manage their targeted drug delivery pump in order to treat chronic pain.
Market Drivers
- Growing Prevalence of Target Diseases
- Favorable Reimbursement Scenario in Major Markets
- Advancements in Technologies and Designs
Opportunities
- Increasing Demand for Biologics and Mabs
- Growth Opportunities in Emerging Markets
Restraints
- Preference for Alternative Drug Delivery Modes and the Possibility of Errors
- Disadvantages Associated With Electronic Device Operation and Functionality
Challenges
- Unfavorable Reimbursement Structure in Developing Countries
Key Target Audience
Electronic Drug Delivery Systems Manufacturers, Component Suppliers, Traders/Distributors/Exporters/Importers, Hospitals & Clinics, End-Use Industries and Others